NCT06899204: Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

Sponsor: Pfizer. Phase: . Conditions: Atopic Dermatitis, Atopic Dermatitis, Unspecified, Dermatitis, Atopic